Assessment of Treg Cells CD4(+)CD25(+) in Chronic Cirrhotic Liver Disease and Hepatocellular Carcinoma Egyptian Patients

Maha El Bassuoni; Mones Obada; Tarek Korah; Sawsan Sayed

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue Accepted Manuscripts All Issues In Press Articles Search

Journal Information Boards and committees Indexing and Listing Sources Publication Ethics and Malpractice Statement Journal Metrics Support Reviewer and AE Registration Form Contact Us Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

Assessment of Treg Cells CD4(+)CD25(+) in Chronic Cirrhotic Liver Disease and Hepatocellular Carcinoma Egyptian Patients

Author(s):

Maha A. El Bassuoni^1,*,

Mones A. Obada²,

Tarek Korah²,

Sawsan El Sayed²

1Department of Clinical Pathology, Faculty of Medicine, Menoufiyia University, [email protected], Egypt

2Department of Clinical Pathology, Faculty of Medicine, Menoufiyia University, Egypt

Hepatitis Monthly:Vol. 8, issue 3; 173-177

Published online:Sep 30, 2008

Article type:Research Article

Received:May 22, 2008

Accepted:Jul 24, 2008

How to Cite:El Bassuoni M A, Obada M A, Korah T, Sayed S E. Assessment of Treg Cells CD4(+)CD25(+) in Chronic Cirrhotic Liver Disease and Hepatocellular Carcinoma Egyptian Patients.Hepat Mon.2008;8(3):173-177.

Abstract

Background and Aims: Dysfunction of the host immune system in cancer patients can be due to a number of factors, including secretion of tumor-derived immunosuppressive factors or induction of immune tolerance against tumor-specific antigens. Several studies suggest that suppression of tumor-associated antigen reactivates lymphocytes by CD4+ CD25+ regulatory T (Treg) cells. This study was designed to evaluate whether CD4+CD25+ Treg cells in chronic liver disease and hepatocellular carcinoma (HCC) patients exhibit an expanded Treg pool and to correlate it with liver tumor markers and grading.

Methods: Blood samples were collected from 20 patients with cirrhotic liver disease (CLD), 15 HCC patients and 10 healthy control subjects. Alpha feto-protein (AFP), HBV and HCV antibodies were detected by EIA. HCV was confirmed by immunoblotting and RT-PCR. To evaluate HCC grading, abdominal ultrasound guided liver biopsy was done. Patients were categorized into moderately differentiated (grade II) and poorly differentiated (grade III) groups. Cytometric analysis of CD4+CD25+ Treg cells in PBMCs was performed using anti-CD3, anti-CD4, anti-CD25, anti-CD45RA, and IgG-isotype control (FITC and PE).

Results: Both CLD and HCC groups were 80% positive for HCV while only 20% of CLD and 11% of HCC patients were positive for HBV. The mean percentage of CD4+CD25+T cell population demonstrated a highly significant increase in comparing HCV to HCC patients [2.47±0.66 vs. 8.96±1.38 (P<0.001)] and when comparing both group to controls [1.15±0.5 (P<0.01)]. Nine HCC patients were in grade II while 6/15 were in grade III. Their mean CD4+CD25+ T cells percentage was 9.12±1.52 and 8.73±1.33, respectively. A negative correlation was found between mean CD4+CD25+ T cells percentage and AFP serum level in HCC patients (r=-0.923) while Treg cells with patients tumor grades (II and III) (r=0.474 and 0.582, respectively). CLD showed a significant correlation with AFP level (r= 0.962).

Conclusions: Tumor specific Treg cells may limit the efficacy of anti-tumor response. Treg cells correlate properly with the unique marker AFP and with tumor grades. Better understanding of the underlying mechanism of Treg regulation or of the strategy for controlling Treg cells may lead to effective HCV immunotherapy and enhancing immunity against cancer.

Keywords

CD4(+)CD25(+) Treg Cell

HCV

Hepatocellular Carcinoma

Liver Cirrhosis

Full Text

Full text is available in PDF

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Maha El Bassuoni:[PubMed][Scholar]
Mones Obada:[PubMed][Scholar]
Tarek Korah:[PubMed][Scholar]
Sawsan Sayed:[PubMed][Scholar]